Jennifer L Reed

US Patent:

7354584, Apr 8, 2008

Filed:

Apr 12, 2004

Appl. No.:

10/823253

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US
Herren Wu - Boyds MD, US
Ying Tang - San Diego CA, US
Julian Davies - San Diego CA, US
Jeffry D. Watkins - Encinitas CA, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
G01N 33/53

US Classification:

4241451, 4241331, 5303913, 5303873, 53038823

Abstract:

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

US Patent:

7371383, May 13, 2008

Filed:

Apr 11, 2003

Appl. No.:

10/412703

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US
William Dall'Acqua - Gaithersburg MD, US
Jacques Van Snick - Wezembeek-Oppem, BE
Jean-Christophe Renauld - Kraainem, BE
Francoise Cormont - Rixensart, BE
Catherine Uyttenhove - Louvain-La-neuve, BE

Assignee:

MedImmune, Inc. - Gaithersburg MD
Ludwig Institute for Cancer Research - New York NY

International Classification:

A61K 39/395

US Classification:

4241451, 53038823, 424133

Abstract:

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

US Patent:

7582297, Sep 1, 2009

Filed:

Apr 12, 2004

Appl. No.:

10/823810

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/24

US Classification:

4241411, 4241301, 53038823, 5303871

Abstract:

The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.

US Patent:

8481037, Jul 9, 2013

Filed:

Jan 14, 2011

Appl. No.:

13/007211

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US
Herren Wu - Boyds MD, US
Ying Tang - San Diego CA, US
Julian Davies - San Diego CA, US
Jeffry Watkins - Encinitas CA, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241451, 4241781

Abstract:

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

US Patent:

20070071746, Mar 29, 2007

Filed:

Aug 30, 2006

Appl. No.:

11/512267

Inventors:

Jennifer Reed - Clarksburg MD, US
Wendy White - Germantown MD, US
Anthony Coyle - Washington DC, US
Alexander Kozhich - Rockville MD, US
Jack Elias - Woodbridge CT, US

Assignee:

MEDIMMUNE, INC. - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/44

US Classification:

424133100, 530388150

Abstract:

The invention relates to the novel discovery that antagonizing a C/CLP can be useful for the treatment of diseases associated with the upregulation of one or more C/CLP such as Th2-driven and/or IL-13 mediated inflammatory diseases. Accordingly the present invention provides C/CLP antagonists and also provides compositions and methods for the prevention, management, treatment or amelioration of an inflammatory condition associated with the upregulation of a C/CLP or one or more symptoms thereof and/or the inhibition of IL-13 mediated inflammation.

US Patent:

20080299134, Dec 4, 2008

Filed:

Mar 17, 2008

Appl. No.:

12/049566

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US
William Dall'Acqua - Gaithersburg MD, US
Jacques Van Snick - Wezembeek-Oppem, BE
Jean-Christophe Renauld - Kraainem, BE
Francoise Cormont - Rixensart, BE
Catherine Uyttenhove - Louvain-La-Neuve, BE

Assignee:

MedImmune, Inc. - Gaithersburg MD
Ludwig Institute for Cancer Research - New York NY

International Classification:

A61K 39/395
C07K 16/18
A61P 43/00

US Classification:

4241721, 5303873

Abstract:

The application describes neutralizing chimeric and humanized anti-human IL-9 antibodies, and the use thereof to identify neutralizing epitopes on human IL-9 and as medicaments to prevent and treat asthma, bronchial hyperresponsiveness, atopic allergy, and other related disorders. Particularly disclosed are recombinant antibodies derived from three murine anti-human IL-9 antibodies identified infra as MH9A3, MH9D1, and MH9L1.

US Patent:

20090047277, Feb 19, 2009

Filed:

Jun 27, 2007

Appl. No.:

11/769326

Inventors:

Jennifer Lynne REED - Clarksburg MD, US
Herren Wu - Boyds MD, US
Ying Tang - San Diego CA, US
Julian Davies - San Diego CA, US
Jeffry D. Watkins - Encinitas CA, US

Assignee:

MEDIMMUNE, INC. - Gaithersburg MD

International Classification:

A61K 39/395
C07K 16/18
G01N 33/53
A61P 43/00

US Classification:

4241331, 5303873, 5303913, 5303917, 435 71

Abstract:

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

US Patent:

20090186038, Jul 23, 2009

Filed:

Feb 24, 2009

Appl. No.:

12/391644

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US

Assignee:

Medlmmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395

US Classification:

4241581

Abstract:

The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present invention encompasses combination therapies, pharmaceutical compositions, articles of manufacture, and kits.